Vivos Therapeutics (NASDAQ: VVOS) reported Q2 EPS of ($0.55), $0.16 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $3.78 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.